Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–66. https://doi.org/10.1056/NEJMra1514009.

Article  CAS  PubMed  Google Scholar 

Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98. https://doi.org/10.1038/s41574-019-0176-8.

Article  PubMed  Google Scholar 

Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32(9):1431–7. https://doi.org/10.1038/ijo.2008.102.

Article  CAS  Google Scholar 

Ri M, Aikou S, Seto Y. Obesity as a surgical risk factor. Ann Gastroenterol Surg. 2017;2(1):13–21. https://doi.org/10.1002/ags3.12049.

Article  PubMed  PubMed Central  Google Scholar 

Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62. https://doi.org/10.1210/jc.2014-3415.

Article  CAS  PubMed  Google Scholar 

Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58: 101882. https://doi.org/10.1016/j.eclinm.2023.101882.

Article  PubMed  PubMed Central  Google Scholar 

Michos ED, Lopez-Jimenez F, Gulati M. Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity. J Am Heart Assoc. 2023;12: e029282. https://doi.org/10.1161/JAHA.122.029282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanovski SZ, Yanovski JA. Progress in pharmacotherapy for obesity. JAMA. 2021;326(2):129–30. https://doi.org/10.1001/jama.2021.9486.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hinnen D. Glucagon-like peptide-1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202–10. https://doi.org/10.2337/ds16-0026.

Article  PubMed  PubMed Central  Google Scholar 

Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326(20):1316–22. https://doi.org/10.1056/NEJM199205143262003.

Article  CAS  PubMed  Google Scholar 

Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661–71. https://doi.org/10.1038/35007534.

Article  CAS  PubMed  Google Scholar 

Rameshrad M, Razavi BM, Lalau JD, De Broe ME, Hosseinzadeh H. An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: a drug repositioning. Iran J Basic Med Sci. 2020;23(5):556–68. https://doi.org/10.22038/ijbms.2020.41638.9832.

Article  PubMed  PubMed Central  Google Scholar 

Commissioner of the FDA. FDA approves new medication for chronic weight management. FDA. 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management

Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3–14. https://doi.org/10.1002/osp4.84.

Article  CAS  PubMed  Google Scholar 

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183.

Article  CAS  PubMed  Google Scholar 

Harris E. Oral semaglutide led to similar weight loss as injection, company says. JAMA. 2023;329(20):2011. https://doi.org/10.1001/jama.2023.9601.

Article  PubMed  Google Scholar 

Prillaman M. Four key questions on the new wave of anti-obesity drugs. Nature. 2023;620(7971):28–30. https://doi.org/10.1038/d41586-023-02445-4.

Article  CAS  PubMed  Google Scholar 

Hvistendahl M, Brandt CF, Tribler S, et al. Effect of liraglutide treatment on jejunostomy output in patients with short bowel syndrome: an open-label pilot study. JPEN J Parenter Enteral Nutr. 2018;42(1):112–21. https://doi.org/10.1177/0148607116672265.

Article  CAS  PubMed  Google Scholar 

He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513–9. https://doi.org/10.1001/jamainternmed.2022.0338.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu J, Liu H, Zhou Q, Wang MW, Li Z. A potentially serious adverse effect of GLP-1 receptor agonists. Acta Pharm Sin B. 2023;13(6):2291–3. https://doi.org/10.1016/j.apsb.2023.02.020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faillie JL, Yin H, Yu OHY, Herrero A, Altwegg R, Renoux C, et al. Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes. Clin Pharmacol Ther. 2022;111(2):272–82. https://doi.org/10.1002/cpt.2430.

Article  CAS  PubMed  Google Scholar 

Mathew A, Hannoodee H. Tirzepatide associated partial small bowel obstruction: a case report. J Endocr Soc. 2023;7(1):bvad114.862. https://doi.org/10.1210/jendso/bvad114.862

Gandhi A, Khanam V, Peterson D, Patel F, Kulairi Z. Dulaglutide commonly known as Trulicity; an anti-diabetic medication causing small bowel obstruction. J Endocr Soc. 2020;4(Suppl 1):MON-681. https://doi.org/10.1210/jendso/bvaa046.609

Jones A, Silver HJ. Myosteatotic and sarcopenic obesity impact postoperative outcomes more robustly than visceral obesity in general surgery patients, with differences by sex. Clin Nutr. 2023;42(3):625–35. https://doi.org/10.1016/j.clnu.2023.03.005.

Article  PubMed  Google Scholar 

Massimino E, Izzo A, Riccardi G, Della PG. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms. Cells. 2021;10(8):1958. https://doi.org/10.3390/cells10081958.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bacelar G, Sampaio E, Alcântara W, Lustoza JG, Daltro C. How to diagnose sarcopenic obesity in candidates for bariatric surgery? Bariatr Surg Pract Patient Care. 2022;17(4):237–40. https://doi.org/10.1089/bari.2021.0085.

Article  Google Scholar 

Zhang X, Zhao Y, Chen S, Shao H. Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. J Cachexia Sarcopenia Muscle. 2021;12(5):1368–79. https://doi.org/10.1002/jcsm.12838.

Article  PubMed  PubMed Central  Google Scholar 

Liang MK, Bernardi K, Holihan JL, et al. Modifying risks in ventral hernia patients with prehabilitation: a randomized controlled trial. Ann Surg. 2018;268(4):674–80. https://doi.org/10.1097/SLA.0000000000002961.

Article  PubMed  Google Scholar 

Jones PM, Hobai IA, Murphy PM. Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution! Can J Anaesth. 2023;70(9):1281–6. https://doi.org/10.1007/s12630-023-02550-y.

Article  CAS  PubMed  Google Scholar 

Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19–28. https://doi.org/10.1177/2042018814559725.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36(6):843–54. https://doi.org/10.1038/ijo.2011.158.